MEDICLIN Aktiengesellschaft

XTRA:MED Stock Report

Market Cap: €138.7m

MEDICLIN Future Growth

Future criteria checks 3/6

MEDICLIN is forecast to grow earnings and revenue by 63.2% and 0.7% per annum respectively.

Key information

63.2%

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth22.4%
Revenue growth rate0.7%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Nov 2024

Recent future growth updates

Recent updates

Is MEDICLIN (ETR:MED) Using Too Much Debt?

Jan 22
Is MEDICLIN (ETR:MED) Using Too Much Debt?

Optimistic Investors Push MEDICLIN Aktiengesellschaft (ETR:MED) Shares Up 26% But Growth Is Lacking

Jan 22
Optimistic Investors Push MEDICLIN Aktiengesellschaft (ETR:MED) Shares Up 26% But Growth Is Lacking

Pinning Down MEDICLIN Aktiengesellschaft's (ETR:MED) P/S Is Difficult Right Now

Mar 29
Pinning Down MEDICLIN Aktiengesellschaft's (ETR:MED) P/S Is Difficult Right Now

Here's Why MEDICLIN (ETR:MED) Has A Meaningful Debt Burden

Oct 27
Here's Why MEDICLIN (ETR:MED) Has A Meaningful Debt Burden

MEDICLIN (ETR:MED) Has Debt But No Earnings; Should You Worry?

May 19
MEDICLIN (ETR:MED) Has Debt But No Earnings; Should You Worry?

MEDICLIN (ETR:MED) Has Debt But No Earnings; Should You Worry?

Feb 18
MEDICLIN (ETR:MED) Has Debt But No Earnings; Should You Worry?

MEDICLIN's (ETR:MED) Stock Price Has Reduced 44% In The Past Three Years

Dec 07
MEDICLIN's (ETR:MED) Stock Price Has Reduced 44% In The Past Three Years

Earnings and Revenue Growth Forecasts

XTRA:MED - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202676322N/AN/A1
12/31/202575219N/AN/A1
12/31/202473016N/AN/A1
9/30/2024766-114588N/A
6/30/2024764-153878N/A
3/31/2024772-63878N/A
12/31/2023762-114078N/A
9/30/2023752201750N/A
6/30/2023734121648N/A
3/31/20237237939N/A
12/31/20227199935N/A
9/30/2022713113557N/A
6/30/2022716194664N/A
3/31/202270196581N/A
12/31/202168416582N/A
9/30/2021662-96482N/A
6/30/2021662-146382N/A
3/31/2021652-1698120N/A
12/31/2020662-993119N/A
9/30/2020674-179111N/A
6/30/2020669-267108N/A
3/31/202068052973N/A
12/31/2019680102570N/A
9/30/201966521260N/A
6/30/20196654-148N/A
3/31/20196617-1532N/A
12/31/20186518-1828N/A
9/30/20186390-1032N/A
6/30/20186354N/A27N/A
3/31/20186245N/A26N/A
12/31/20176154N/A20N/A
9/30/201760919N/A19N/A
6/30/201759914N/A23N/A
3/31/201759115N/A25N/A
12/31/201658317N/A30N/A
9/30/201658217N/A29N/A
6/30/201657019N/A33N/A
3/31/201656117N/A32N/A
12/31/201555517N/A31N/A
9/30/201555013N/A30N/A
6/30/201554612N/A28N/A
3/31/201554211N/A31N/A
12/31/20145389N/A32N/A
9/30/20145297N/A27N/A
6/30/20145254N/A20N/A
3/31/20145232N/A20N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MED is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: MED is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MED is expected to become profitable in the next 3 years.

Revenue vs Market: MED's revenue (0.7% per year) is forecast to grow slower than the German market (5.6% per year).

High Growth Revenue: MED's revenue (0.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MED's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 09:00
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MEDICLIN Aktiengesellschaft is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Karl-Heinz ScheunemannLandesbank Baden-Wuerttemberg Equity and Fixed Income Research
Klaus SchloteSolventis Wertpapierhandelsbank GmbH
Nico LoechnerSolventis Wertpapierhandelsbank GmbH